[go: up one dir, main page]

IL299376A - Pertuzuniab plus trastuzumab fixed dose combination - Google Patents

Pertuzuniab plus trastuzumab fixed dose combination

Info

Publication number
IL299376A
IL299376A IL299376A IL29937622A IL299376A IL 299376 A IL299376 A IL 299376A IL 299376 A IL299376 A IL 299376A IL 29937622 A IL29937622 A IL 29937622A IL 299376 A IL299376 A IL 299376A
Authority
IL
Israel
Prior art keywords
fdc
patient
pertuzumab
trastuzumab
administering
Prior art date
Application number
IL299376A
Other languages
Hebrew (he)
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of IL299376A publication Critical patent/IL299376A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Claims (38)

1. PATENT Attorney Docket No. P36105-WO
2. WHAT IS CLAIMED IS: 1. A method of treating HER2-positive cancer in a patient comprising administering a loading dose of a fixed dose combination (FDC) of pertuzumab, trastuzumab, and recombinant human hyaluronidase (rHuPH20) by subcutaneous injection in a thigh of the patient with a subcutaneous administration device at a rate of about 2 mL/min over about minutes. 2. The method of claim 1, wherein the loading dose FDC comprises 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units of rHuPH20.
3. The method of claim 1 or claim 2, wherein the volume for the loading dose FDC is 15 mL.
4. The method of any one of the preceding claims, wherein the loading dose FDC comprises 1200 mg pertuzumab at a concentration of 80 mg/mL, 600 mg trastuzumab at a concentration of 40 mg/mL, 2000 U/mL rHuPH20, 20 mM His-HCl pH 5.5, 70 mM trehalose, 133 mM sucrose, 0.04% polysorbate 20, and 10 mM methionine.
5. The method of any one of the preceding claims, wherein administration of the loading dose FDC is followed by an about 30 minute observation period.
6. The method of any one of the preceding claims, further comprising administering maintenance doses of FDC in a thigh of the patient at a rate of about 2 mL/min over about minutes.
7. The method of claim 6, wherein the maintenance dose FDC comprises 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units of rHuPH20.
8. The method of claim 6 of claim 7, wherein the volume for the maintenance dose FDC is mL.
9. The method of any one of claims 6 to 8, wherein the maintenance dose FDC comprises 600 mg pertuzumab at a concentration of 60 mg/mL, 600 mg trastuzumab at a concentration of 60 mg/mL, 2000 U/mL rHuPH20, 20 mM His-HCl pH 5.5, 105 mM trehalose, 100 mM sucrose, 0.04% polysorbate 20, and 10 mM methionine.
10. The method of any one of claim 6 to 9, wherein each maintenance dose is followed by an about 15 minute observation period, and wherein the loading dose was well tolerated.
11. The method of any one of the preceding claims, wherein the subcutaneous administration device is a hand-held syringe.
12. The method of claim 11, wherein the syringe comprises a 25G-27G hypodermic injection needle.
13. The method of any one of the preceding claims, wherein the HER2-positive cancer is breast cancer.
14. The method of any one of the preceding claims, wherein the breast cancer is early breast cancer (EBC). Attorney Docket No. P36105-WO
15. The method of claim 14, wherein the FDC is used for neoadjuvant or adjuvant therapy of the EBC.
16. The method of claim 13, wherein the breast cancer is metastatic breast cancer (MBC).
17. The method of any one of claims 1 to 13, wherein the FDC is used for: a. neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; b. adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence; or c. in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
18. The method of any one of the preceding claims, comprising: a. administering the FDC to the patient; b. monitoring the patient for hypersensitivity symptoms or injection-related reaction; and c. slowing down or pausing the injection, wherein the patient has a significant injection-related reaction or permanently discontinuing the FDC if the patient experiences anaphylaxis or has a severe injection-related reaction.
19. The method of any one of the preceding claims, comprising pre-medicating the patient prior to administering the FDC with an analgesic, antipyretic, or antihistamine, wherein a Grade 1 or Grade 2 hypersensitivity reaction has occurred with a prior administration of the FDC.
20. The method of any one of the preceding claims, comprising alternating the subcutaneous injection site for each administration of the FDC between a left and right thigh of the patient.
21. A method of neoadjuvant therapy of HER2-positive early breast cancer patients comprising: a. administering a fixed dose combination (FDC) of pertuzumab, trastuzumab, and recombinant human hyaluronidase (rHuPH20) by subcutaneous injection to the patients; and b. measuring treatment-emergent anti-pertuzumab, anti-trastuzumab, and anti-recombinant human hyaluronidase PH20 antibodies in the patients, wherein treatment-emergent antibodies occur in ≤ about 10% of the patients.
22. The method of claim 21, wherein treatment-emergent anti-pertuzumab, anti-trastuzumab, and anti-recombinant rHuPH20 antibodies occur in about 4.8%, 0.9%, and 0.9% of the patients, respectively. Attorney Docket No. P36105-WO
23. The method of claim 21 or claim 22, further comprising measuring whether any treatment-emergent antibodies neutralize pertuzumab’s, trastuzumabs, and/or rHuPH20’s activity.
24. A method of neoadjuvant therapy of HER2-positive early breast cancer comprising administering a pertuzumab plus trastuzumab fixed dose combination (FDC) and chemotherapy to the patient.
25. The method of claim 24, which achieves a pathological complete response (pCR) of about 60%.
26. The method of claim 24 or claim 25, wherein the chemotherapy comprises anthracycline and taxane.
27. The method of claim 26, wherein the FDC is administered following completion of the anthracycline and the taxane is administered after the FDC is administered.
28. The method of any one of claims 24 to 27, wherein the chemotherapy comprises dose dense anthracycline (ddAC) and paclitaxel.
29. The method of claim 28, comprising administering ddAC every 2 weeks for 4 cycles (q2w x 4) followed by FDC every 3 weeks for 4 cycles (q3w x 4) in combination with paclitaxel every week for 12 weeks (qw x 12).
30. The method of any one of claims 24 to 27, wherein the chemotherapy comprises anthracycline and cyclophosphamide (AC) and docetaxel.
31. The method of claim 30, comprising administering AC every 3 weeks for 4 cycles (q3w x 4) followed by FDC every 3 weeks for 4 cycles (q3w x 4) in combination with docetaxel (75 mg/m esclated to 100 mg/m if the initial dose is well tolerated) every 3 weeks for cycles (q3w x 4).
32. The method of any one of claims 24 to 31, comprising administering FDC to the patient following surgery q3w for about 1 year (up to 18 cycles).
33. The method of any one of claims 24 to 32, wherein the patient has hormone receptor-negative cancer.
34. The method of any one of claims 24 to 33, wherein the patient has stage II-IIIA cancer.
35. The method of any one of claims 24 to 34, wherein the patient has node-positive cancer.
36. The method of any one of claims 24 to 35, wherein the cancer is HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive).
37. A method of treating a HER2-positive cancer patient to whom trastuzumab and pertuzumab has been previously administered intravenously comprising: a. administering a fixed dose combination (FDC) comprising 600 mg of pertuzumab and 600 mg of trastuzumab, wherein the patient received previous intravenous pertuzumab and trastuzumab < 6 weeks earlier; or Attorney Docket No. P36105-WO b. administering a fixed dose combination (FDC) comprising 1200 mg of pertuzumab and 600 mg of trastuzumab, wherein the patient received previous intravenous pertuzumab and trastuzumab ≥ 6 weeks earlier.
38. A fixed dose combination (FDC) of pertuzumab, trastuzumab, and recombinant human hyaluronidase (rHuPH20) for use in a method of treating HER2-positive cancer in a patient, wherein the method comprises administering a loading dose of said combination by subcutaneous injection in a thigh of the patient with a subcutaneous administration device at a rate of about 2 mL/min over about 8 minutes.
IL299376A 2020-06-29 2020-09-11 Pertuzuniab plus trastuzumab fixed dose combination IL299376A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063045712P 2020-06-29 2020-06-29
US202063065795P 2020-08-14 2020-08-14
PCT/US2020/050363 WO2022005499A1 (en) 2020-06-29 2020-09-11 Pertuzumab plus trastuzumab fixed dose combination

Publications (1)

Publication Number Publication Date
IL299376A true IL299376A (en) 2023-02-01

Family

ID=72659343

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299376A IL299376A (en) 2020-06-29 2020-09-11 Pertuzuniab plus trastuzumab fixed dose combination

Country Status (11)

Country Link
US (2) US12252549B2 (en)
EP (1) EP4171748A1 (en)
JP (1) JP2023532122A (en)
KR (2) KR20230030621A (en)
CN (1) CN115916834A (en)
AU (1) AU2020456731A1 (en)
BR (1) BR112022026888A2 (en)
CA (1) CA3185613A1 (en)
IL (1) IL299376A (en)
MX (1) MX2022015884A (en)
WO (1) WO2022005499A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
ES3023516T3 (en) 2011-10-14 2025-06-02 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
CA2907776C (en) 2013-04-16 2020-04-14 Genentech, Inc. Pertuzumab variants and evaluation thereof
CN117752782A (en) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 Subcutaneous HER2 antibody formulation
KR20190096384A (en) 2017-03-02 2019-08-19 제넨테크, 인크. HER2-positive breast cancer adjuvant treatment
US11077059B2 (en) 2017-07-25 2021-08-03 Elektrofi, Inc. Electrospraying formation of particles including agents
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
JP2023522627A (en) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド Method of forming particles by continuous droplet formation and dehydration
TW202400230A (en) 2022-03-14 2024-01-01 美商建南德克公司 Combination therapies for breast cancer
US20250082736A1 (en) * 2023-09-08 2025-03-13 Elektrofi, Inc. Particles and suspensions comprising hyaluronan degrading agents and methods of use thereof
WO2025122745A1 (en) 2023-12-05 2025-06-12 Genentech, Inc. Combination therapies for treatment of her2 cancer
WO2025158306A1 (en) * 2024-01-25 2025-07-31 Intas Pharmaceuticals Ltd. Novel high concentration phesgo formulation

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587657D1 (en) 1984-01-30 1993-12-23 Imp Cancer Res Tech IMPROVEMENTS IN GROWTH FACTORS.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
DE68926248T2 (en) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "new" human protein and the use of this protein for the detection of preneoplasmic or neoplasmic in humans
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
JP3951062B2 (en) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CN102416176A (en) 1995-07-27 2012-04-18 基因技术股份有限公司 Stabile isotonic lyophilized protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
ES2293661T3 (en) 1996-11-27 2008-03-16 Genentech, Inc. PURIFICATION FOR POLYPEPTIDE AFFINITY IN A PROTEIN MATRIX A.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
DE69938923D1 (en) 1998-03-27 2008-07-31 Genentech Inc SYNERGY BETWEEN APO-2 LIGAND AND ANTIBODY AGAINST HER-2
KR101036414B1 (en) 1998-05-06 2011-05-23 제넨테크, 인크. Protein purification method by ion exchange chromatography
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
WO2000069460A1 (en) 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR100754049B1 (en) 1999-06-25 2007-08-31 제넨테크, 인크. Anti-ErbB2 Antibodies and Compositions Used in the manufacture of a medicament for the treatment of prostate cancer
KR20090126330A (en) 1999-08-27 2009-12-08 제넨테크, 인크. Anti-ERR2 Antibody Administration Treatment Methods
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
KR20080038458A (en) 2000-05-19 2008-05-06 제넨테크, 인크. Genetic detection assays to improve the likelihood of an effective response to cancer therapy with ERW antagonists
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US6695940B2 (en) 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
EP1300146A1 (en) 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
JP2005522514A (en) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド Modified anti-HER2 antibody
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
WO2004024866A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Protein purification
EP1572972A4 (en) 2002-11-21 2007-11-21 Genentech Inc THERAPY OF BENIGN DISEASES OR DISORDERS USING ANTI-ERBB2 ANTIBODIES
TW555245U (en) 2003-01-29 2003-09-21 Hon Hai Prec Ind Co Ltd Cable connector assembly
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050025753A1 (en) 2003-04-30 2005-02-03 Wei Han Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
LT3095793T (en) 2003-07-28 2020-07-10 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
CA2563341C (en) 2004-04-08 2014-10-21 David B. Agus Erbb antagonists for pain therapy
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
SV2006002143A (en) 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
KR20180004850A (en) 2004-07-22 2018-01-12 제넨테크, 인크. Her2 antibody composition
US20060067930A1 (en) 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
PL1846030T3 (en) 2005-01-21 2019-05-31 Genentech Inc Fixed dosing of her antibodies
EP3195879A1 (en) 2005-02-23 2017-07-26 Genentech, Inc. Extending time to disease progression or survival in cancer patients
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc HERCEPTIN® adjuvant therapy
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (en) 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007067597A2 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2007145862A2 (en) 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
MY150756A (en) 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
US8529901B2 (en) 2007-06-06 2013-09-10 Hoffmann-La Roche, Inc. Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR101584823B1 (en) 2007-09-12 2016-01-22 제넨테크, 인크. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
PL2840090T3 (en) 2007-10-30 2018-07-31 Genentech, Inc. Antibody purification by cation exchange chromatography
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
WO2009111707A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
NZ621433A (en) 2008-03-18 2015-10-30 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR079256A1 (en) 2009-12-04 2012-01-04 Genentech Inc METHOD FOR THE TREATMENT OF METASTASIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1
CN103476407A (en) 2010-12-09 2013-12-25 霍夫曼-拉罗奇有限公司 Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
JP6385060B2 (en) 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト In vivo selection of therapeutically active antibodies
ES3023516T3 (en) 2011-10-14 2025-06-02 Hoffmann La Roche Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
KR101915942B1 (en) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
AR094403A1 (en) 2013-01-11 2015-07-29 Hoffmann La Roche ANTI-HER3 ANTIBODY COMBINATION THERAPY
CA2907776C (en) 2013-04-16 2020-04-14 Genentech, Inc. Pertuzumab variants and evaluation thereof
CN112353943A (en) 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 Methods of treating cancer with PD-1 axis binding antagonists and taxanes
KR20160141857A (en) 2014-04-25 2016-12-09 제넨테크, 인크. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
RU2727663C2 (en) 2014-09-17 2020-07-22 Дженентек, Инк. Immunoconjugates, containing antibodies against her2 and pyrrolbenzodiazepines
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3534948A1 (en) * 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
CA3046092A1 (en) 2016-12-28 2018-07-05 Genentech, Inc. Treatment of advanced her2 expressing cancer
CN117752782A (en) * 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 Subcutaneous HER2 antibody formulation
KR20190096384A (en) 2017-03-02 2019-08-19 제넨테크, 인크. HER2-positive breast cancer adjuvant treatment
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
US20190145985A1 (en) * 2017-11-10 2019-05-16 BioAgilytix Labs, LLC Method for eliminating target interference
TWI841551B (en) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 Combination therapy with targeted 4-1bb (cd137) agonists
US20200157208A1 (en) * 2018-11-19 2020-05-21 Eli Lilly And Company Combination of an antibody that binds to the p19 subunit of human il-23 and a hyaluronidase enzyme
WO2022013189A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
EP4259662A1 (en) 2020-12-11 2023-10-18 Genentech, Inc. Combination therapies for treatment of her2 cancer
TW202400230A (en) 2022-03-14 2024-01-01 美商建南德克公司 Combination therapies for breast cancer

Also Published As

Publication number Publication date
US20210403599A1 (en) 2021-12-30
US12252549B2 (en) 2025-03-18
CA3185613A1 (en) 2022-01-06
US20250333540A1 (en) 2025-10-30
EP4171748A1 (en) 2023-05-03
JP2023532122A (en) 2023-07-26
KR20250151568A (en) 2025-10-21
CN115916834A (en) 2023-04-04
BR112022026888A2 (en) 2023-03-14
WO2022005499A1 (en) 2022-01-06
AU2020456731A1 (en) 2023-01-05
MX2022015884A (en) 2023-04-03
KR20230030621A (en) 2023-03-06

Similar Documents

Publication Publication Date Title
IL299376A (en) Pertuzuniab plus trastuzumab fixed dose combination
AU2013402794B2 (en) Cancer treatment with combination of plinabulin and taxane
RU2019125238A (en) ANTIBODIES AGAINST HER2 FOR SUBcutaneous administration
JP2020515519A5 (en)
Murray et al. Aflibercept for radiation maculopathy study: a prospective, randomized clinical study
JP2012136535A (en) Docetaxel in combination with rhumab her2 for treatment of cancer
JP2020509024A5 (en)
JP2020510667A5 (en)
RU2015152860A (en) INTRODUCTION MODE AND COMPOSITIONS FOR TYPE B Adenoviruses
TW202033188A (en) Treatment of cancer by combination of immune checkpoint inhibitor and FOLFIRINOX therapy
JP2025148449A5 (en)
WO2000040229A2 (en) Synergistic tumorcidal response induced by histamine
CN111166878B (en) Preparation method and application of combination of antibody targeting tumor antigen and iNKT cell
IL292332A (en) Methods for treating her2-positive breast cancer with toctinib in combination with capecitabine and trastuzumab
JP2005529152A5 (en)
Ammor et al. 5PSQ-151 optimisation of the subcutaneous administration of daratumumab
RU2524309C1 (en) Method for selecting therapeutic approach to locally advanced prostate cancer
Shreiber Erenumab (Aimovig) for migraine prophylaxis in adults
JPWO2020112765A5 (en)
CN111840541A (en) Application of polyinosinic acid cytidylic acid combined with anti-CD47 antibody in tumor therapy
David et al. Effectiveness of turmeric mouthwash and sodium bicarbonate mouthwash to reduce oral mucositis among patient undergoing radiation therapy
NZ781127B2 (en) Mirikizumab for use in a method of treating crohn&#39;s disease
Severson Evaluating the benefits of transitioning from intravenous to subcutaneous Rituximab for Alberta cancer patients
Cheung et al. Galcanezumab (Emgality) for Migraine and Cluster Headaches
Feltham Send in the clones